Takeda has announced that its pioglitazone-containing medicines for type 2 diabetes have had their overall benefits ratified by the European Commission.
The body has adopted the European Medicines Agency Committee for Medical Products for Human Use's opinion that pioglitazone remains a valid treatment option for certain diabetes patients, despite its potential associated risks.
The body has adopted the European Medicines Agency Committee for Medical Products for Human Use's opinion that pioglitazone remains a valid treatment option for certain diabetes patients, despite its potential associated risks.